



CCS/CTS Canadian Thoracic Society Position Statement on Pulmonary Hypertension

Panel Member's Relationships with Industry (RWI)

The CCS is committed to preserving the scientific integrity of its Guidelines and Position Statements through transparency and management of relationships with industry (RWI). Panel members must disclose all relationships with industry regardless of relevance to the statement topic (see below). When a potential conflict exists, the affected member must recuse during the formal consensus voting process. For more information on the CCS Guideline Development process, please visit www.ccs.ca.

Affiliations with commercial organizations within the previous two years that may have a direct or indirect connection to the content of this statement.

Member	Consulting Fees/ Honoraria	Clinical Trials	Other Financial Benefit	Relevance to Statement
Primary Panel				
Lisa Mielniczuk	Actelion, Bayer, Pharmascience, Servier	Bayer	None	
David Langleben	Actelion, Bayer, Northern Therapeutics, PhaseBio, United Therapeutics	Arena, Actelion, Bayer, Northern Therapeutics	None	None
Sanjay Mehta	Actelion/Janssen, Bayer, Natco	Actelion/Janssen, Bellerophon, Eiger, Gilead, Reata, United Therapeutics	None	None
Kim Connelly	Bristol-Myers Squibb, Boehringer Ingelheim, Janssen, Lilly, Merck, Novartis, Servier	Amgen, Boehringer Ingelheim	None	
Nathan Brunner	Bayer, Actelion	Bayer, Actelion	None	
Naushad Hirani	Bayer, Actelion	Bayer, Bellerophon, Gilead, United Therapeutics	None	
Ali Kapasi	Bayer, Boehringer Ingelheim, GlaxoSmithKline, Roche, Actelion	Bayer, Boehringer Ingelheim, Sanofi, Actelion	None	
Secondary Panel				
Stephen Archer	None	None	None	
George Chandy	Bayer, Actelion Pharmaceuticals, Janssen	Bayer, Actelion Pharmaceuticals, Janssen	None	
John Granton	Bayer, Actelion, United Therapeutics (DSMC, Steering, Adjudication committees)	Bayer, Eli Lilly, Pfizer, United Therapeutics, Ikaria, Belleraphron, Eiger, Janssen Pharmaceuticals	None	Lilly, Pfizer, Ikaria, Bayer and Janssen Pharmaceuticals have medication for pulmonary hypertension in market.
Simon Jackson	Bayer	None	None	
Lisa Lee	Actelion Global	None	None	
Jamie Myrah	None	None	None	
Ian Paterson	None	None	None	
Sharon Proudfoot	None	None	None	
Lawrence Rudski	None	None	General Electric - minor shareholder	

Affiliations with commercial organizations within the previous two years that may have a direct or indirect connection to the content of this statement.

Member	Consulting Fees/ Honoraria	Clinical Trials	Other Financial Benefit	Relevance to Statement
Duncan Stewart	Bayer	Northern Therapeutics/United Therapeutics	Northern Therapeutics/United Therapeutics	
John Swiston	Bayer, Actelion	Bayer, Novartis, Actelion, Reata, United Therapeutics	None	
Linda Webster	None	Bayer, Bellerophon, United Therapeutics	None	